Table 1. Baseline characteristics.
| Features | S1+Cisplatin (%) | 5Fu+Cisplatin (%) | P value |
|---|---|---|---|
| Age | |||
| Mean±SD | 53.27±12.14 | 55.33±11.16 | 0.177 |
| Gender | |||
| Male | 84 (70.0) | 85 (73.3) | |
| Female | 36 (30.0) | 31 (26.7) | 0.577 |
| Race | |||
| Han | 116 (96.7) | 111 (95.7) | |
| Others | 4 (3.3) | 5 (4.3) | 0.695 |
| Histology | |||
| Low differentiated | 57 (47.5) | 65 (56.0) | |
| Moderate differentiated | 28 (23.3) | 17 (14.7) | |
| High differentiated | 2 (1.7) | 5 (4.3) | |
| Others | 33 (27.5) | 29 (25.0) | 0.190 |
| Location | |||
| Stomach | 70(58.33%) | 73(62.93%) | |
| GE junction | 22(18.33%) | 10(8.62%) | |
| Stomach and GE junction | 28(23.33%) | 33(28.45%) | 0.086 |
| Sites of metastasis | |||
| 1 | 18(15.00%) | 18(15.52%) | |
| >1 | 102(85.00%) | 98(84.48%) | 0.912 |
| Previous gastrectomy | |||
| Yes | 65(54.17%) | 64(55.17%) | |
| No | 55(45.83%) | 52(44.83%) | 0.877 |
| PS | |||
| 0 | 28(23.33%) | 29(25.00%) | |
| 1 | 85(70.83%) | 83(71.55%) | |
| 2 | 7(5.83%) | 4(3.45%) | 0.673 |
SD: Standard deviation; GE: Gastroesophageal; PS: Performance status